Aabakken L, Larsen S, Osnes M
Ullevål Hospital, Medical Dept., Oslo, Norway.
Scand J Rheumatol. 1989;18(6):361-8. doi: 10.3109/03009748909102097.
To study the protective effect of Sucralfate on Naproxen-induced mucosal lesions, 16 healthy, male volunteers were given Naproxen 500 mg b.i.d. together with Sucralfate 2 g b.i.d. or placebo in a double-blind, crossover study. Drug periods were 1 week, with a 3-week wash out in between. Mucosal lesions in stomach and duodenum were assessed by upper endoscopy before and after each drug period, using a visual analogue with separate scoring of mid- and distal duodenal lesions. 51Cr-EDTA absorption tests were performed to demonstrate possible changes in distal gut permeability. In addition, subjective symptoms were registered. Both drug periods induced significant lesions in the stomach and duodenum. Statistically speaking, fewer changes were found in the stomach and duodenal bulb after Sucralfate co-administration, whereas no significant reduction of lesions was seen in the distal duodenum. The 51Cr-EDTA absorption was increased in both periods, indicating deleterious effects to distal parts of the gut, but our results did not demonstrate Sucralfate-mediated protection from these changes. Symptoms were modest, and equal in the two periods. We conclude that Sucralfate may offer protection in the gastric and proximal duodenal mucosa, but no such protective effect was seen distally to the duodenal bulb.
为研究硫糖铝对萘普生诱导的黏膜损伤的保护作用，在一项双盲、交叉研究中，16名健康男性志愿者每日两次服用500毫克萘普生，同时每日两次服用2克硫糖铝或安慰剂。给药期为1周，期间有3周的洗脱期。在每个给药期前后，通过上消化道内镜检查评估胃和十二指肠的黏膜损伤情况，使用视觉模拟评分法分别对十二指肠中、远端损伤进行评分。进行51铬-乙二胺四乙酸（51Cr-EDTA）吸收试验以证明远端肠道通透性可能发生的变化。此外，记录主观症状。两个给药期均在胃和十二指肠诱导出显著损伤。从统计学角度而言，联合使用硫糖铝后，胃和十二指肠球部的变化较少，而十二指肠远端的损伤未见显著减轻。两个给药期的51Cr-EDTA吸收均增加，表明对肠道远端有有害影响，但我们的结果未显示硫糖铝对这些变化有保护作用。症状较轻，且两个给药期相同。我们得出结论，硫糖铝可能对胃和十二指肠近端黏膜有保护作用，但在十二指肠球部远端未观察到这种保护作用。
